SCHEMBL486031

SCHEMBL486031

CCNc1nc(-c2ccc(NC(=O)NCc3cnc(N)c(C)c3)c(F)c2)ccc1C(=O)NCCN1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.40
ATR Q13535 5/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 2/20 0.38
IKBKB O14920 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
CHRNA7 P36544 1/20 0.37
KCNH2 Q12809 1/20 0.37
KIT P10721 1/20 0.37
EPHX2 P34913 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
SCN9A Q15858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485908 0.91 PIK3CA (0.41) MAP4K4ATRMEN1KMT2AIKBKB
SCHEMBL485903 0.91 PIK3CA (0.41) MAP4K4ATRMEN1KMT2AIKBKB
SCHEMBL486437 0.90 TRPV1 (0.41) MAP4K4MEN1KMT2AIKBKBCHRNA7
SCHEMBL485853 0.90 PIK3CA (0.41) MAP4K4ATRMEN1KMT2AIKBKB
SCHEMBL3048779 0.90 ATR (0.45) MAP4K4ATRCHRNA7KCNH2KIT
SCHEMBL486392 0.89 MEN1 (0.39) MAP4K4ATRMEN1KMT2AIKBKB
SCHEMBL485906 0.89 MEN1 (0.40) MEN1KMT2AIKBKBCHRNA7KCNH2
SCHEMBL486108 0.88 IKBKB (0.41) MAP4K4MEN1KMT2AIKBKBCHRNA7
SCHEMBL486297 0.88 NAMPT (0.41) MAP4K4MEN1KMT2AIKBKBTLR7
SCHEMBL486093 0.87 PIK3CA (0.39) MAP4K4MEN1KMT2AMAPK1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US claimed
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP disclosed
WO-2010109122-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS NAMPT, NNT, NQO1 MAP4K4 1932/4885ATR 3247/4885MEN1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.